Vmbook Online ordering

Medical Laboratories Research

Foundation Medicine (FMI) is a molecular information company that provides a full spectrum of comprehensive genomic profiling solutions to capture the complexity of tumors and support precision medicine in oncology.

Historically, FMI has reported positive revenue growth over the past few years. In 2019, the company reported total revenue of $199.8 million, representing an increase of 23% compared to $162.3 million in 2018. However, the company has not been profitable and has reported net losses for the past several years. In 2019, the net loss was $55.6 million, compared to a net loss of $59.2 million in 2018.

In terms of earnings, FMI has not generated positive earnings per share (EPS) and the company's net loss has impacted its earnings growth negatively. In 2019, the company reported a diluted net loss per share of $1.25, compared to a diluted net loss per share of $1.43 in 2018.

Despite the lack of profitability, FMI has a strong position in the market for comprehensive genomic profiling and has collaborations with several major pharmaceutical companies, which provides a solid foundation for future growth. The company's focus on precision medicine and its commitment to advancing cancer diagnostics and treatments is expected to drive long-term growth. However, investors should be aware of the company's negative earnings and the associated risks.

In January 2021, it was announced that Roche, a major shareholder of FMI, has agreed to acquire the remaining shares of FMI for $137 per share in cash, which represents a premium of 29% over the previous closing price. This acquisition is expected to help Roche expand its personalized cancer care offerings and improve patient outcomes. The acquisition is subject to customary closing conditions and regulatory approvals and is expected to close in the first half of 2021.